- Alkermes reported total revenues of $390.7 million in Q2 2025, with proprietary product net sales of $307.2 million, reflecting 14% year-over-year growth.
- Cost of goods sold decreased to $49.5 million from $61.5 million in Q2 2024, reflecting manufacturing efficiencies.
- GAAP net income was $87.1 million, EBITDA was $101.6 million, and adjusted EBITDA was $126.5 million for the quarter.
- Gross to net favorability contributed approximately $20 million tailwind in Q2 due to Medicaid utilization rates and other credits.
- R&D expenses increased to $77.4 million from $59.6 million, driven by investments in Phase II studies of alixorexton.
- SG&A expenses were $170.8 million, slightly up from $168.1 million in Q2 2024, with expectations of stable to modestly decreasing expenses in H2 2025.
- The company ended Q2 with $1.05 billion in cash and investments and $200 million remaining share repurchase authorization.
Related items and other data are not available for this feed item.
Dafinchi